BR0114100A - Formulações de liberação controlada para administração oral - Google Patents

Formulações de liberação controlada para administração oral

Info

Publication number
BR0114100A
BR0114100A BR0114100-7A BR0114100A BR0114100A BR 0114100 A BR0114100 A BR 0114100A BR 0114100 A BR0114100 A BR 0114100A BR 0114100 A BR0114100 A BR 0114100A
Authority
BR
Brazil
Prior art keywords
oral administration
controlled release
release formulations
pharmaceutical composition
reported
Prior art date
Application number
BR0114100-7A
Other languages
English (en)
Inventor
Badri Narayanan Vishwanathan
Ashok Rampal
Gour Mukherji
S Rajeev Raghuvanshi
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IN856DE2000 external-priority patent/IN192864B/en
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of BR0114100A publication Critical patent/BR0114100A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin

Abstract

"FORMULAçõES DE LIBERAçãO CONTROLADA PARA ADMINISTRAçãO ORAL". A presente invenção refere-se a uma composição farmacêutica na forma de uma dosagem sólida que compreende uma quantidade eficaz de uma droga ou de seus sais farmaceuticamente aceitáveis. Também é relatada uma composição farmacêutica adequada para um regime de dosagem diária.
BR0114100-7A 2000-09-22 2001-09-22 Formulações de liberação controlada para administração oral BR0114100A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN856DE2000 IN192864B (pt) 2000-09-22 2000-09-22
IN881DE2001 2001-08-24
PCT/IB2001/001743 WO2002024203A2 (en) 2000-09-22 2001-09-22 Controlled release formulations for oral administration

Publications (1)

Publication Number Publication Date
BR0114100A true BR0114100A (pt) 2003-10-21

Family

ID=26324883

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0114100-7A BR0114100A (pt) 2000-09-22 2001-09-22 Formulações de liberação controlada para administração oral

Country Status (9)

Country Link
US (1) US20020119192A1 (pt)
EP (1) EP1322313A2 (pt)
KR (1) KR20030048410A (pt)
CN (1) CN1471398A (pt)
AP (1) AP2003002763A0 (pt)
AU (1) AU2001287977A1 (pt)
BR (1) BR0114100A (pt)
MX (1) MXPA03002569A (pt)
WO (1) WO2002024203A2 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003253121A1 (en) * 2002-08-02 2004-02-25 Ranbaxy Laboratories Limited Storage stable tablets of fosinopril sodium
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
WO2004096182A1 (en) * 2003-04-30 2004-11-11 Ranbaxy Laboratories Limited Extended release matrix tablets of carvedilol
CN104397869B (zh) 2003-11-07 2016-06-08 美国无烟烟草有限责任公司 烟草组合物
US8627828B2 (en) 2003-11-07 2014-01-14 U.S. Smokeless Tobacco Company Llc Tobacco compositions
ES2603856T3 (es) 2004-03-29 2017-03-01 Les Laboratoires Servier Procedimiento para preparar una composición farmacéutica sólida
US20050220873A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
US20050260263A1 (en) * 2004-05-18 2005-11-24 Panion & Bf Biotech Inc. Sustained release formulation for sparingly soluble main drugs
US20060045911A1 (en) * 2004-08-27 2006-03-02 Sun Pharmaceutical Industries Ltd. Stable pharmaceutical formulations
US20070092565A1 (en) * 2005-10-25 2007-04-26 Pharmascience Inc. Gastric retention drug delivery system
EP2170294A1 (en) * 2007-06-25 2010-04-07 Pharmathen S.A. Improved pharmaceutical formulation containing an hmg-coa reductase inhibitor and method for the preparation thereof
US20120027855A1 (en) * 2007-07-06 2012-02-02 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
MX340249B (es) 2008-08-15 2016-07-01 Depomed Inc Composiciones farmacéuticas retentivas gástricas para tratamiento y prevención de transtornos del sistema nervioso central (cns).
EP2349221A4 (en) * 2008-10-08 2013-03-27 Bioplus Life Sciences Pvt Ltd DELIVERING MEDICATION DELIVERY SYSTEM
WO2010106555A2 (en) * 2009-03-17 2010-09-23 Shantilal, Doshi, Bimalkumar Directly compressible pre-granulated cellulose ether polymer and process for preparing the same
WO2011101866A2 (en) * 2010-02-17 2011-08-25 Sun Pharma Advanced Research Company Ltd., A method of treating a disease condition susceptible to baclofen therapy
MX2015001751A (es) 2012-08-07 2015-11-13 Topgenix Inc Composicion topica comprendiendo bacterias transformadas que expresan un compuesto de interes.
EP3236954B1 (en) * 2014-12-23 2022-03-23 DuPont Nutrition USA, Inc. Enteric film coating compositions, method of coating, and coated forms
US11324774B2 (en) * 2018-01-05 2022-05-10 Augusta University Research Institute, Inc. Compositions of oral alkaline salts and metabolic acid inducers and uses thereof
CN110840866A (zh) * 2018-08-20 2020-02-28 成都新睿泰康科技有限公司 一种细辛脑药物组合物及其在防治神经退行性疾病方面的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772470A (en) * 1985-04-27 1988-09-20 Nitto Electric Industrial Co., Ltd. Oral bandage and oral preparations
US5686094A (en) * 1991-04-01 1997-11-11 Theratech, Inc. Controlled release formulations for the treatment of xerostomia
ATE170745T1 (de) * 1991-04-08 1998-09-15 Nippon Shinyaku Co Ltd Kapsel mit langzeitwirkung fuer die adhäsion im gastrointestinaltrakt
AU2367900A (en) * 1998-12-18 2000-07-03 Bayer Corporation Chewable drug delivery system
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions

Also Published As

Publication number Publication date
KR20030048410A (ko) 2003-06-19
WO2002024203A2 (en) 2002-03-28
US20020119192A1 (en) 2002-08-29
WO2002024203A3 (en) 2002-11-07
AU2001287977A1 (en) 2002-04-02
MXPA03002569A (es) 2003-10-14
EP1322313A2 (en) 2003-07-02
AP2003002763A0 (en) 2003-03-31
CN1471398A (zh) 2004-01-28

Similar Documents

Publication Publication Date Title
BR0114100A (pt) Formulações de liberação controlada para administração oral
CU23468B7 (es) Forma de dosificación de pramipexol en una dosis única diaria
BRPI0518266A2 (pt) medicamento oral de libertaÇço modificada de pelo menos um princÍpio ativo sob a forma multimicrocapsular
ES2170069T3 (es) 1-alfa-hidroxiprevitamina d para administracion oral.
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
BR122012014331A8 (pt) Formulações farmacêuticas
ES2156028T3 (es) Composiciones que contienen tetrahidrolipstatina
BR0115382A (pt) Formulações para liberação controlada de hidrocodona, método de produzir analgesia efetiva, processo de preparação de uma forma farmacêutica de um sólido oral de liberação controlada, liberação controlada da forma farmacêutica oral e uso da forma farmacêutica
YU13695A (sh) Upotreba 2-fenil-3-aroilbenzotiofena i njihove farmaceutske formulacije
BR0015346A (pt) Formulação farmacêutica contendo tolterodina e seu uso
RS50368B (sr) Levodopa/karbidopa/entakapon farmaceutski preparat
CO5261517A1 (es) Composiciones farmaceuticas analgesicas que contienen buprenorfina/naloxona, buprenorfina/naltrexona o buprenorfina/nalmefen en bajas dosis
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
CO5390076A1 (es) Composiciones farmaceuticas
BR0210261A (pt) Formulações farmacêuticas para a administração eficiente de apomorfina, 6ar-(-)-n-propil-norapomorfina e seus derivados e pró-drogas destes
ES2175663T3 (es) Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis.
BR0211198A (pt) Composições farmacêuticas e seu uso
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
BR0014440A (pt) Formulações de liberação controlada oral
BR0108313A (pt) Composição farmacêutica para injeção intramuscular contendo loxoprofeno
HRP20020258B1 (en) Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
YU81101A (sh) Polimorfni oblici kristalnog citrata azabiciklo (2,2,2) oktan-3-amina i njihovih farmaceutskih kompozicija
PE20020903A1 (es) Metodo para prevenir la diarrea

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 1964 DE 26/08/2008 E CONSIDERANDO A AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS.